newsfilter
← Latest News
PR Newswire·

Triple-Gene Announces Completion of Enrollment and Dosing in Phase 1 Trial of INXN‑4001, First Multigenic Investigational Therapeutic Candidate for Treatment of Heart Failure

Triple-Gene LLC, a clinical stage cardiovascular gene therapy company and majority owned subsidiary of Intrexon Corporation (NASDAQ: XON), today...